Hypera SA ADR (HYPMY)
Hypera S.A. ADR is a depositary receipt representing common stock of Hypera S.A., a Brazilian pharmaceutical company listed on OTC Markets. Through its operations in Brazil, the company markets a broad portfolio of healthcare products, including sweeteners, analgesics and anti-inflammatories, cold and flu remedies, decongestants, antihistamines, antiseptics, herbal medicines, gastrointestinal products, generics, skincare items, supplements, vitamins, and other consumer health brands. Its products are sold under brands such as Adocyl, Doril, Buscopan, Neosaldina, neo quimica, and Addera. Founded in 1999 and headquartered in São Paulo, Brazil, the company was previously known as Hypermarcas S.A. before adopting the Hypera S.A. name in February 2018.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-HYPM.Y
|
$6
|
48.2% Upside
|
Undervalued
|
—
|
—
|
—
|
Good
|
—
|
—
|
0.18
|
3.2%
|
August 6, 2026
|
9.0x
|
1.1x
|
1.7x
|
2.959 B
|
4.16 B
|
36.8%
|
43.3%
|
7.7
|
44.4%
|
123.4%
|
